Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool below to find open protocols for your type of cancer. To learn more about eligibility and participation call 877-789-6100.

Search by conditions: 

Click a protocol # to view extended details on a particular clinical trial.

Protocol #DescriptionPhase
14-035 A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation  (View details on clinicaltrial.gov)Phase I
13-517 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma  (View details on clinicaltrial.gov)Phase III
13-587A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the MEK Inhibitor, trametinib, Combined with the CDK4/6 Inhibitor, palbociclib, To Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity in Subjects with Solid Tumors  (View details on clinicaltrial.gov)Phase II
14-031A Multicenter Phase 1A/1B Ascending Dose Study of DCC-2701 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Metastatic Melanoma  (View details on clinicaltrial.gov)Phase I
06-097A Multicenter Phase I Study of the Treatment of Recurrent Primary CNS Lymphoma with Alimta (Pemetrexed), a Novel Anti-Folate  (View details on clinicaltrial.gov)Phase I
12-274A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer  (View details on clinicaltrial.gov)Phase II
10-179A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients with Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor  (View details on clinicaltrial.gov)Phase II
12-254A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer  (View details on clinicaltrial.gov)Phase I
13-412A Multicenter, Open-label, Phase 1b Study of MLN0128 (an Oral mTORC1/2 Inhibitor) in Combination With MLN1117 (an Oral PI3Kα Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies  (View details on clinicaltrial.gov)Phase I
05-275A Multicenter, Open-Label, Single-Arm Study of Yondelis (trabectedin) for Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma who have Relapsed or are Refractory Standard Treatment  (View details on clinicaltrial.gov)Phase II
13-068A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer  (View details on clinicaltrial.gov)Phase III
14-127A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy  (View details on clinicaltrial.gov)Phase III
14-049A Multicenter, Randomized, Open-label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients With Advanced Multiple Myeloma  (View details on clinicaltrial.gov)Phase II
13-126A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 in Combination With Radiation Plus Temozolomide or Temozolomide Alone for Subjects With Glioblastoma Multiforme  (View details on clinicaltrial.gov)Phase I
11-474A Phase 1 Study of AEB071, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma  (View details on clinicaltrial.gov)Phase I
14-191A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms  (View details on clinicaltrial.gov)Phase I
13-581A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Previously Treated Multiple Myeloma  (View details on clinicaltrial.gov)Phase I
13-360A Phase 1 Study of LY2875358 in Patients with Advanced Cancer  (View details on clinicaltrial.gov)Phase I
13-523A Phase 1 Study of LY3009120 in Patients with Advanced or Metastatic Cancer  (View details on clinicaltrial.gov)Phase I
13-134A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Biological Activity of SAR405838 in Patients With Advanced Cancer  (View details on clinicaltrial.gov)Phase I
13-321A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia  (View details on clinicaltrial.gov)Phase I
12-312A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults with Ovarian Cancer and other FOLR1-Positive Solid Tumors  (View details on clinicaltrial.gov)Phase I
11-429A Phase 1, Multicenter, Open-Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma  (View details on clinicaltrial.gov)Phase I
14-045A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation  (View details on clinicaltrial.gov)Phase I
13-371A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation  (View details on clinicaltrial.gov)Phase I
11-217A Phase 1, Open Label, Dose Escalation Study of MGA271 (Fcoptimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3  (View details on clinicaltrial.gov)Phase I
12-461A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas  (View details on clinicaltrial.gov)Phase I
12-191A Phase 1, Open-Label, Multicenter Study of ACY-1215 in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma  (View details on clinicaltrial.gov)Phase I
11-502A Phase 1, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)  (View details on clinicaltrial.gov)Phase I
13-344A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, and Pharmakokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9291 in Patients with Advanced Non Small Cell Lung Cancer who have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent (AURA)  (View details on clinicaltrial.gov)Phase I
11-425A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, as Monotherapy and in Combination With Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma  (View details on clinicaltrial.gov)Phase II
14-177A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma  (View details on clinicaltrial.gov)Phase II
12-098A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov)Phase II
12-014A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients with Smoldering Multiple Myeloma  (View details on clinicaltrial.gov)Phase I
14-189A Phase 1a/1b Study of the Oral TRK Inhibitor LOXO-101 in Subjects With Adult Solid Tumors  (View details on clinicaltrial.gov)Phase I
11-164A Phase 1b Clinical Trial of LDE225 in Combination With Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) in Previously Untreated Locally Advanced or Metastatic Pancreatic Adenocarcinoma, With an Expansion Cohort at the Recommended Phase 2 Dose  (View details on clinicaltrial.gov)Phase I
13-595A Phase 1b Dose Escalation Study of OMP-54F28 in Combination with Sorafenib in Patients with Hepatocellular Cancer  (View details on clinicaltrial.gov)Phase I
13-170A Phase 1B Dose-escalation Study of TRC105 in Combination with Axitinib in Patients with Advanced Renal Carcinoma  (View details on clinicaltrial.gov)Phase I
12-154A Phase 1b Study of Intermittent Administration of High Doses of the Irreversible EGFR Inhibitor Afatinib as a Means of Achieving Plasma Levels Active Against Non-small Cell Lung Cancer With Known T790M Mutations  (View details on clinicaltrial.gov)Phase I
13-562A Phase 1b, Open Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Axitinib(AG-013736) In Combination with Crizotinib(PF-02341066)in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov)Phase I
13-491A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination with Conatumumab in Subjects with Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer  (View details on clinicaltrial.gov)Phase I
13-557A Phase 1B/2 Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 in Combination with Pomalidomide and Low-Dose Dexamethasome in Patients with Relapsed-and-Refractory Multiple Myeloma  (View details on clinicaltrial.gov)Phase II
12-464A Phase 1B/2 Study To Evaluate The Safety And Efficacy Of PF-04449913, An Oral Hedgehog Inhibitor, In Combination With Intensive Chemotherapy, Low Dose Ara-C Or Decitabine In Patients With Acute Myeloid Leukemia Or High Risk Myelodysplastic Syndrome  (View details on clinicaltrial.gov)Phase I
13-559A Phase 2 Pilot Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Cancer  (View details on clinicaltrial.gov)Phase II
11-380A Phase 2 Study of Brentuximab Vedotin in Patients With CD30-positive Non-Hodgkin Lymphoma  (View details on clinicaltrial.gov)Phase II
13-148A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients with Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations  (View details on clinicaltrial.gov)Phase II
12-321A Phase 2, Controlled Trial, of a Single ProHema-CB Unit (Ex Vivo CXCR4-Upregulated CD34+ Hematopoietic Progenitor Cells, Cord Blood) as Part of a Double Umbilical Cord Blood Transplant Following Myeloablative Conditioning for Patients Age 15-55 Years with Hematologic Malignancies  (View details on clinicaltrial.gov)Phase II
13-572A Phase 2, multicenter, open-label study of BGJ398 in patients with recurrent resectable or unresectable Glioblastoma  (View details on clinicaltrial.gov)Phase II
11-449A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies  (View details on clinicaltrial.gov)Phase II
13-496A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)  (View details on clinicaltrial.gov)Phase II
11-447A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)  (View details on clinicaltrial.gov)Phase III
11-262A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG in Combination With Cetuximab (Erbitux) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer  (View details on clinicaltrial.gov)Phase III
13-539A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma  (View details on clinicaltrial.gov)Phase III
13-225A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma  (View details on clinicaltrial.gov)Phase III
13-186A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy  (View details on clinicaltrial.gov)Phase III
13-253A Phase I Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov)Phase I
12-487A Phase I Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (BMS-986015) Administered in Combination with Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors  (View details on clinicaltrial.gov)Phase I
12-283A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative Breast Cancer  (View details on clinicaltrial.gov)Phase I
13-606A Phase I Open-label Study of Safety and Tolerability of MEDI4736 in Subjects with Metastatic or Unresectable Melanoma in Combination with Dabrafenib and Trametinib or with Trametinib Alone  (View details on clinicaltrial.gov)Phase I
06-068A Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066. A CMET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer  (View details on clinicaltrial.gov)Phase I
10-457A Phase I Study of Chemoradiation with Midostaurin (PKC412) for Locally Advanced Rectal Cancer  (View details on clinicaltrial.gov)Phase I
13-348A Phase I Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Progressive Lymphoma  (View details on clinicaltrial.gov)Phase I
12-202A Phase I Study of Lenalidomide plus Chemotherapy with Mitoxantrone, Etoposide, and Cytarabine for the Reinduction of Patients with Acute Myelogenous Leukemia  (View details on clinicaltrial.gov)Phase I
12-491A Phase I Study of MM-141 in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov)Phase I
11-351A Phase I Study of Once-Daily External-Beam Partial-Breast Irradiation (PBI) for Selected Patients with Early Invasive N0 or Non-Invasive Breast Cancer  (View details on clinicaltrial.gov)Phase I
12-531A Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With Acute Myeloid Leukemia  (View details on clinicaltrial.gov)Phase I
09-307A Phase I Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients with Advanced, Incurable, Solid Tumor or Hematologic Malignancies in which the Target Kinases Are Linked to Disease Pathophysiology  (View details on clinicaltrial.gov)Phase I
11-253A Phase I Trial of Hypofractionated Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov)Phase I
11-209A Phase I, Dose Escalation Study of INK1117 in Subjects with Advanced Solid Malignancies Followed by Expansion in Subjects with Measurable Disease  (View details on clinicaltrial.gov)Phase I
10-462A Phase I, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects with Advanced Solid Tumors  (View details on clinicaltrial.gov)Phase I
13-251A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 Genes  (View details on clinicaltrial.gov)Phase I
11-186A Phase I, Multi-center, Open-label, Dose Escalation Study of Pasireotide (SOM230) LAR in Patients With Advanced Neuroendocrine Tumors (NETs)  (View details on clinicaltrial.gov)Phase I
10-430A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects with Advanced Malignancies, including Non-Hodgkin Lymphoma, Followed by an Expansion in Subjects with Measurable Disease  (View details on clinicaltrial.gov)Phase I
11-314A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors  (View details on clinicaltrial.gov)Phase I
10-446A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a pan FGF-R kinase inhibitor, in Adult Patients with Advanced Solid Malignancies  (View details on clinicaltrial.gov)Phase I
12-009A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma  (View details on clinicaltrial.gov)Phase I
12-290A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma  (View details on clinicaltrial.gov)Phase I
12-537A Phase I/IB Study of Ipilimumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation  (View details on clinicaltrial.gov)Phase I
14-282A Phase I/II Multicenter, Open-label Study of CLR457, administered Orally in Adult Patients with Advanced Solid Malignancies  (View details on clinicaltrial.gov)Phase II
13-541A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers  (View details on clinicaltrial.gov)Phase II
12-075A Phase I/II Study of the ALK Inhibitor CH5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov)Phase II
11-418A Phase I/II Trial of Multiple Dose VB-111 and Weekly Paclitaxel for the Treatment of Recurrent Platinum-Resistant Müllerian Cancer  (View details on clinicaltrial.gov)Phase I
11-053A Phase I/II, Open-label, Multicenter Study of ACY-1215 Administered Orally As Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma  (View details on clinicaltrial.gov)Phase II
12-048A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients with gBRCA Mutation Breast Cancer or Other Solid Tumor  (View details on clinicaltrial.gov)Phase II
12-114A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination with Gemcitabine in Patients with Metastatic Pancreatic Cancer  (View details on clinicaltrial.gov)Phase II
13-245A Phase Ib Dose Escalation/Randomized Phase II, Multicenter, Open-label Study of BYL719 in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma  (View details on clinicaltrial.gov)Phase I
13-123A Phase Ib Open-label, Dose-escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer  (View details on clinicaltrial.gov)Phase I
11-490A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors  (View details on clinicaltrial.gov)Phase I
12-252A Phase Ib Study of the Safety and Pharmacology of MPDL3280A Administered With Bevacizumab and/or With Chemotherapy in Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov)Phase I
13-157A Phase Ib Trial of BYL719 (an α-Specific PI3K Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer  (View details on clinicaltrial.gov)Phase I
11-277A Phase Ib, Open Label, Dose Escalation Study of the Safety and Pharmacology of GDC-0068 in Combination with Either Docetaxel OR Fluoropyrimidine plus Oxaliplatin in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov)Phase I
12-376A Phase Ib, Open-Label Study of the Safety and Pharmacology of MPDL3280A Administered in Combination with Vemurafenib in Patients with Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma  (View details on clinicaltrial.gov)Phase I
13-199A Phase Ib, Open-label, Dose Escalation Study of LDK378 and AUY922 in Patients With ALK-rearranged Non-small Cell Lung Cancer  (View details on clinicaltrial.gov)Phase I
13-313A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies  (View details on clinicaltrial.gov)Phase II
12-432A Phase Ib/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients with BRAF mutant Metastatic Colorectal Cancer  (View details on clinicaltrial.gov)Phase II
13-283A Phase Ib/II Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive, Her2- Locally Advanced or Metastatic Breast Cancer  (View details on clinicaltrial.gov)Phase II
13-367A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer  (View details on clinicaltrial.gov)Phase II
13-433A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma  (View details on clinicaltrial.gov)Phase II
12-458A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition  (View details on clinicaltrial.gov)Phase II
13-053A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies  (View details on clinicaltrial.gov)Phase II
13-009A Phase II Study of Adjuvant Proton Radiation Therapy for the Treatment of Stage I, IIA and IIB Seminoma  (View details on clinicaltrial.gov)Phase II
13-163A Phase II Study of Eribulin Mesylate in Combination with Trastuzumab and Pertuzumab in Women with Metastatic, Unresectable Locally Advanced, or Locally Recurrent Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer  (View details on clinicaltrial.gov)Phase II
12-498A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma  (View details on clinicaltrial.gov)Phase II
13-220A Phase II Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung  (View details on clinicaltrial.gov)Phase II
10-308A Phase II Study Of Proton Beam Therapy For Locally Advanced Sinonasal Malignancies  (View details on clinicaltrial.gov)Phase II
10-206A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors requiring Partial Brain Irradiation: An Assessment of Long-term Neurocognitive, Neuroendocrine and Ototoxicity Outcomes  (View details on clinicaltrial.gov)Phase II
11-085A Phase II Study of Reduced Intensity, Double Umbilical Cord Blood Transplantation Using Fludarabine, Melphalan, and Low Dose Total Body Radiation  (View details on clinicaltrial.gov)Phase II
10-137A Phase II Study of the HSP Inhibitor STA-9090 in Metastatic Ocular Melanoma  (View details on clinicaltrial.gov)Phase II
11-023A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations  (View details on clinicaltrial.gov)Phase II
11-208A Phase II Trial of Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer With Involvement of Bone  (View details on clinicaltrial.gov)Phase II
11-344A Phase II Trial of HKI-272 (Neratinib) for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases  (View details on clinicaltrial.gov)Phase II
05-326A Phase II Trial of Proton Radiation For The Treatment Of Pediatric Bone And Non- Rhabdomyosarcoma Soft Tissue Sarcomas  (View details on clinicaltrial.gov)Phase II
04-188A Phase II Trial of Proton Radiation for the Treatment of Pediatric Rhabdomyosarcoma  (View details on clinicaltrial.gov)Phase II
13-086A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity  (View details on clinicaltrial.gov)Phase II
11-485A Phase II, 2-stage trial of CRLX101 in Recurrent Ovarian, Tubal and Peritoneal Cancer  (View details on clinicaltrial.gov)Phase II
12-293A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab with and without GDC-0941 in Patients with Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov)Phase II
14-182A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients with PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov)Phase II
13-509A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients with Recurrent High-Grade Glioma  (View details on clinicaltrial.gov)Phase II
14-062A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain  (View details on clinicaltrial.gov)Phase II
10-207A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients with HER2 Negative Primary Tumors and HER2 Positive Circulating Tumor Cells  (View details on clinicaltrial.gov)Phase II
14-029A Phase II, Two-Tier study evaluating the efficacy and safety of Selinexor (KPT-330)in patients with recurrent Glioblastoma after failure of Radiation Thearpy and Temozolomide  (View details on clinicaltrial.gov)Phase II
12-372A Phase IIB/III Randomized, Double-Blind, Placebo-controlled Study Comparing First-Line Therapy with or without TG4010 Immunotherapy Product in Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov)Phase III
13-508A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma  (View details on clinicaltrial.gov)Phase III
13-532A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.  (View details on clinicaltrial.gov)Phase III
14-105A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone as Second-Line Therapy in Patients with Stage IIIb/IV Non-Squamous Non-Small-Cell Lung Cancer  (View details on clinicaltrial.gov)Phase III
13-075A Pilot Feasibility Study of Definitive Concurrent Chemoradiation with Pencil Beam Scanning Proton Beam in Combination with 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal  (View details on clinicaltrial.gov)N/A
12-517A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma  (View details on clinicaltrial.gov)Phase I
13-165A Pilot Study of Oncaspar + Dexamethasone in Patients with Relapsed or Refractory T-Cell Lymphoma  (View details on clinicaltrial.gov)N/A
12-213A Prospective Study of HCV-RNA Kinetics During Treatment With SORAFENIB In Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C  (View details on clinicaltrial.gov)Phase IV
13-327A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer  (View details on clinicaltrial.gov)Phase II
12-028A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma  (View details on clinicaltrial.gov)Phase III
13-021A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma  (View details on clinicaltrial.gov)Phase II
12-084A Randomized Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer  (View details on clinicaltrial.gov)Phase II
13-048A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs Paclitaxel in Combination with Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)  (View details on clinicaltrial.gov)Phase II
12-258A Randomized Phase II Trial of Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide (AC) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations  (View details on clinicaltrial.gov)Phase II
13-138A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma  (View details on clinicaltrial.gov)Phase III
12-219A Randomized Three Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)  (View details on clinicaltrial.gov)Phase II
13-173A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma  (View details on clinicaltrial.gov)Phase III
12-344A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction  (View details on clinicaltrial.gov)Phase III
13-447A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients with Platinum-Resistant Ovarian Cancer  (View details on clinicaltrial.gov)Phase II
13-076A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma  (View details on clinicaltrial.gov)Phase III
12-477A Randomized, Phase II, Placebo-Controlled Study of GDC-0068, an Inhibitor to AKT, in Combination with Fluoropyrimidine Plus Oxaliplatin in Patients with Locally Advanced to Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma  (View details on clinicaltrial.gov)Phase II
10-106A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)  (View details on clinicaltrial.gov)Phase III
13-334A Single Arm, Single Stage Phase II trial of GSK1120212 and GSK2141795 in Persistent or Recurrent Cervical Cancer  (View details on clinicaltrial.gov)Phase II
13-521A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting  (View details on clinicaltrial.gov)Phase III
13-322A Study to Evaluate Vascular Normalization in Patients with Recurrent Glioblastoma Treated with Bevacizumab using [11C]Temozolomide PET and Vascular MRI  (View details on clinicaltrial.gov)N/A
13-482A Study to Evaluate Vascular Normalization in Patients with Recurrent Glioblastoma Treated with Bevacizumab using FMISO PET and Vascular MRI  (View details on clinicaltrial.gov)N/A
14-004A Two Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Arm A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Arm B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors  (View details on clinicaltrial.gov)Phase I
13-232A031203: Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma  (View details on clinicaltrial.gov)Phase II
13-592A041202: A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)  (View details on clinicaltrial.gov)Phase III
13-533A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, Alliance IND #15380) Vaccine Given with Bevacizumab Versus Bevacizumab alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)  (View details on clinicaltrial.gov)Phase II
13-311ABTC-1202:Phase I Study of MK-1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma  (View details on clinicaltrial.gov)Phase I
11-464Afatinib Sequenced with Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial.  (View details on clinicaltrial.gov)Phase II
12-423An Exploratory Study of the Biologic Effects of BMS-936558 (Anti-PD-1 Monoclonal Antibody) Treatment in Subjects with Advanced Melanoma (Unresectable or Metastatic)  (View details on clinicaltrial.gov)Phase I
14-196An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ-197) Protocols  (View details on clinicaltrial.gov)N/A
12-514An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)  (View details on clinicaltrial.gov)Phase III
13-308An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma  (View details on clinicaltrial.gov)Phase III
13-247An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma  (View details on clinicaltrial.gov)Phase II
13-505An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS Mutation-Positive Advanced Solid Tumors  (View details on clinicaltrial.gov)Phase I
13-174An Open-label Phase II Study of BKM120 in Patients With Relapsed and Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma and Follicular Lymphoma  (View details on clinicaltrial.gov)Phase II
09-103An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Tumor of Bone  (View details on clinicaltrial.gov)Phase II
13-615An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification  (View details on clinicaltrial.gov)Phase II
09-468An Open-Label, Phase 2 Trial of Orally Administered PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma (GBM)  (View details on clinicaltrial.gov)Phase II
13-542An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination with Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects with Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma  (View details on clinicaltrial.gov)Phase I
13-043An Open-Label, Phase I Study of ARN-810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer  (View details on clinicaltrial.gov)Phase I
11-492An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma  (View details on clinicaltrial.gov)Phase I
11-010An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer  (View details on clinicaltrial.gov)Phase I
11-274An Open-Label, Phase II Study of Cabozantinib (XL184) in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors After Progression on Prior VEGF Therapy  (View details on clinicaltrial.gov)Phase II
12-097An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers  (View details on clinicaltrial.gov)Phase II
12-528An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)  (View details on clinicaltrial.gov)Phase III
13-074An Open-Label, Three-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the anti-EGFR Antibody Panitumumab in Combination in Subjects with BRAF-mutation V600E Positive Colorectal Cancer  (View details on clinicaltrial.gov)Phase II
14-071An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma  (View details on clinicaltrial.gov)Phase II
13-272Analysis of the kinetics and effects of vemurafenib on intratumoral and host immunity in patients with advanced BRAFV600 mutant melanoma: implications for combination with immunotherapy  (View details on clinicaltrial.gov)N/A
12-518ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer  (View details on clinicaltrial.gov)Phase II
12-188BMT CTN 1101: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) for Patients with Hematologic Malignancies  (View details on clinicaltrial.gov)Phase III
09-346Bortezomib plus Rituximab for Initial Systemic Therapy of EBV+ Post-Transplant Lymphoproliferative Disease (PTLD)  (View details on clinicaltrial.gov)Phase II
10-327CALGB 50801: Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)  (View details on clinicaltrial.gov)Phase II
12-440CALGB 51101: A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma  (View details on clinicaltrial.gov)Phase II
10-259CALGB 80702: Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer  (View details on clinicaltrial.gov)Phase III
84-070CALGB 8461: Cytogenetic Studies in Acute Leukemia  (View details on clinicaltrial.gov)N/A
09-419CALGB 90601: A Randomized Double Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma  (View details on clinicaltrial.gov)Phase III
09-175CERN 08-02: A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma  (View details on clinicaltrial.gov)Phase II
08-207Circulating Tumor Cell Analysis in Patients with Localized Prostate Cancer Undergoing Prostatectomy  (View details on clinicaltrial.gov)N/A
13-492Clinical and Biological Predicators of Chemotherapy Toxicity in Older Adults  (View details on clinicaltrial.gov)N/A
12-211COG AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)  (View details on clinicaltrial.gov)Phase III
12-389COG ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)  (View details on clinicaltrial.gov)Phase II
10-427COG AEWS1031: A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma.  (View details on clinicaltrial.gov)Phase III
09-379COG AHEP0731: Treatment of Children with All Stages of Hepatoblastoma  (View details on clinicaltrial.gov)Phase III
04-112COG ANBL0032: Phase III Randomized Study of Chimerica Antibody 14.18 (Ch 14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue  (View details on clinicaltrial.gov)Phase III
13-120COG: AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD  (View details on clinicaltrial.gov)Phase III
10-239COG-ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years  (View details on clinicaltrial.gov)Phase III
11-476COG-ARENO534: Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor  (View details on clinicaltrial.gov)Phase III
12-343COMBAT 1: A Phase II Trial of Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma  (View details on clinicaltrial.gov)Phase II
13-054COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection  (View details on clinicaltrial.gov)Phase III
12-530COMETI Phase 2: Characterization of Circulating Tumor Cells from Subjects with Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index  (View details on clinicaltrial.gov)Phase II
12-005Dose Finding Pilot Study of Cabozantinib (XL184) Administered Orally as Monotherapy for the Treatment of Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With Bone Disease  (View details on clinicaltrial.gov)Phase I
09-194E2607 - A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas  (View details on clinicaltrial.gov)Phase II
11-275ECOG 1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon Alpha-2b for Resected High-Risk Melanoma  (View details on clinicaltrial.gov)Phase III
13-465ECOG 3612: A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma  (View details on clinicaltrial.gov)Phase II
12-452GOG: 279 Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC#613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva  (View details on clinicaltrial.gov)Phase II
10-218Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma  (View details on clinicaltrial.gov)N/A
09-273HOD08: Reduced Duration Stanford V Chemotherapy with Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma  (View details on clinicaltrial.gov)Phase II
12-490Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial  (View details on clinicaltrial.gov)Phase III
13-209Investigator-Initiated, Pilot Translational Study of Circulating Tumor Cells to Identify Predictive Factors of Response to Abiraterone Acetate in Men with Castration-Resistant Prostate Cancer.  (View details on clinicaltrial.gov)N/A
10-111N0577: Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma  (View details on clinicaltrial.gov)Phase III
12-538N1174: Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme  (View details on clinicaltrial.gov)Phase II
12-023NCCTG-N1048: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision  (View details on clinicaltrial.gov)Phase III
12-434NSABP PROTOCOL B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer  (View details on clinicaltrial.gov)Phase III
12-466Open-label, Phase 2 Study of Bevacizumab in Children with Neurofibromatosis 2 and Progressive Vestibular Schwannomas that are Poor Candidates for Standard Treatment with Surgery or Radiation  (View details on clinicaltrial.gov)Phase II
13-529Open-label, Single-arm, Phase 2 Study of the Initial and Post-Transplant Treatment with Carfilzomib, Lenalidomide and Low dose Dexamethasone (CRd) in Transplant Candidates with Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy  (View details on clinicaltrial.gov)Phase II
13-339Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination with Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma  (View details on clinicaltrial.gov)Phase I
11-318Phase 1, Multicenter, Open-label, Dose-escalation Study of ACE-011 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma  (View details on clinicaltrial.gov)Phase I
13-010Phase 1/2 Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523, an ERK 1/2 Inhibitor, in Patients With Advanced Malignancies  (View details on clinicaltrial.gov)Phase I
13-408Phase 1/2 Study of PF-06463922 (an ALK/ROS1 Tyrosine Kinase Inhibitor) In Patients With Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations  (View details on clinicaltrial.gov)Phase II
13-362Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma  (View details on clinicaltrial.gov)Phase II
12-008Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies  (View details on clinicaltrial.gov)Phase II
13-073Phase 2 Combination Trial of Tivozanib and Enzalutamide in Men with Advanced Prostate Cancer  (View details on clinicaltrial.gov)Phase II
13-190Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Following Failure of Prior Therapy With at Least 1 Tyrosine Kinase Inhibitor  (View details on clinicaltrial.gov)Phase II
11-216Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors  (View details on clinicaltrial.gov)Phase III
11-072Phase I Dose Escalation Study to Determine the MTD and DLTs of Preoperative or Definitive Administration of Nilotinib Given Concurrently with Radiation for Patients with High Risk Chordoma  (View details on clinicaltrial.gov)Phase I
13-198Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer  (View details on clinicaltrial.gov)Phase I
12-267Phase I Study of Afatinib with Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)  (View details on clinicaltrial.gov)Phase I
13-115Phase I Study of Olaparib and Temozolomide in Adult Patients with Recurrent/Metastatic Ewing's Sarcoma following failure of prior chemotherapy  (View details on clinicaltrial.gov)Phase I
10-329Phase I Study of Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma  (View details on clinicaltrial.gov)Phase I
11-385Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma  (View details on clinicaltrial.gov)Phase I
12-159Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer  (View details on clinicaltrial.gov)Phase I
12-396Phase I Trial of Bevacizumab, Metronomic Doxorubicin, and Radiation Therapy for Resectable Soft Tissue Sarcomas  (View details on clinicaltrial.gov)Phase I
13-239Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)  (View details on clinicaltrial.gov)Phase I
12-094Phase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-vs.-Host Disease(GVHD)  (View details on clinicaltrial.gov)Phase I
13-040Phase I Trial of Brentuximab Vedotin With Re-induction Chemotherapy in Patients With Relapsed, CD30 Expressing, Acute Myeloid Leukemia (AML)  (View details on clinicaltrial.gov)Phase I
13-363Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)  (View details on clinicaltrial.gov)Phase I
12-185Phase I/II Study of AMG 386 with and without Bevacizumab for Recurrent Glioblastoma  (View details on clinicaltrial.gov)Phase II
09-293Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer  (View details on clinicaltrial.gov)Phase II
13-424Phase I/II study of Dabrafenib, Trametinib, and Navitoclax in BRAF mutant melanoma and other solid tumors  (View details on clinicaltrial.gov)Phase II
12-100Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) with Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas  (View details on clinicaltrial.gov)Phase II
13-543Phase Ib Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance and Preliminary Antineoplastic Activity of Gemcitabine Administered in Combination with Continuous Intravenous Doses of PRI-724, a CBP/ β- Catenin Inhibitor, to Patients with Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy After Failing First-Line Therapy with FOLFIRINOX (or FOLFOX)  (View details on clinicaltrial.gov)Phase I
14-197Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients with Recurrent Glioblastoma Multiforme (GBM)  (View details on clinicaltrial.gov)Phase II
14-056Phase II Double-Blind Randomized Controlled Trial of Naltrexone for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer  (View details on clinicaltrial.gov)Phase II
13-051Phase II Feasibility Study of FOLFIRINOX-Losartan followed by Accelerated Short Course Radiation Therapy with Proton Beam for Locally Advanced Pancreatic Cancer  (View details on clinicaltrial.gov)Phase II
13-376Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib with SAR245409 or of Pimasertib with SAR245409 Placebo in Subjects with Previously Treated Unresectable Low Grade Ovarian Cancer  (View details on clinicaltrial.gov)Phase II
12-484Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR  (View details on clinicaltrial.gov)Phase II
13-411Phase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted Therapy (NCI number 9312)  (View details on clinicaltrial.gov)Phase II
10-113Phase II Study of Carboplatin and Pralatrexate in Patients with Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer  (View details on clinicaltrial.gov)Phase II
10-116Phase II Study of Dose-Adjusted EPOCH-Rituxan in Adults with Untreated Burkitt Lymphoma and c-MYC Positive Diffuse Large B-Cell Lymphoma  (View details on clinicaltrial.gov)Phase II
10-139Phase II Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases  (View details on clinicaltrial.gov)Phase II
11-073Phase II Study of Neoadjuvant Accelerated Short Course Radiation Therapy with Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer  (View details on clinicaltrial.gov)Phase II
11-328Phase II Study of Preoperative FOLFIRINOX followed by Accelerated Short Course Radiation Therapy for Borderline-Resectable Pancreatic Cancer  (View details on clinicaltrial.gov)Phase II
09-131Phase II Study of Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma  (View details on clinicaltrial.gov)Phase II
09-263Phase II Study of Proton Radiation Therapy for CNS Germ Cell Tumors; Evaluation of Acute and Late Side Effects  (View details on clinicaltrial.gov)Phase II
10-439Phase II Study of Proton Radiation Therapy for Low Grade Gliomas  (View details on clinicaltrial.gov)Phase II
12-091Phase II Trial of Cabozantinib (XL184) in Patients with Advanced Solid (Non-breast, Non-prostate) Malignancies and Bony Metastases  (View details on clinicaltrial.gov)Phase II
09-457Phase II Trial of CAPOX + Bevacizumab + Trastuzumab for Patients with HER2-Positive Metastatic Esophagogastric Cancer  (View details on clinicaltrial.gov)Phase II
13-249Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults  (View details on clinicaltrial.gov)Phase II
12-218Phase II Trial of Sorafenib in Combination with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma  (View details on clinicaltrial.gov)Phase II
13-522Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy  (View details on clinicaltrial.gov)Phase III
11-497Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Low or Low-intermediate Risk Prostate Cancer  (View details on clinicaltrial.gov)Phase III
10-269Pilot Study of Adjuvant Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix with Metastases to Regional Lymph Nodes  (View details on clinicaltrial.gov)N/A
13-018Pilot study of MET-PET (L-[methyl-11C]methionine positron emission tomography) to evaluate for treatment response after chemoradiation therapy for newly-diagnosed glioblastoma  (View details on clinicaltrial.gov)N/A
10-205Pilot Study of Proton Radiation Therapy for Invasive Carcinoma of the Left Breast Following Mastectomy  (View details on clinicaltrial.gov)N/A
09-361Proton beam Radiotherapy for Medulloblastoma and Pineoblastoma: An Assessment of Acute Toxicity and Long-term Neurocognitive, Neuroendocrine and Ototoxicity Outcomes  (View details on clinicaltrial.gov)Phase II
11-021Proton stereotactic body radiation therapy (SBRT) for medically inoperable, peripheral early-stage non-small cell lung cancer (NSCLC): A pilot study  (View details on clinicaltrial.gov)N/A
13-520Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer  (View details on clinicaltrial.gov)Phase III
12-504Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation  (View details on clinicaltrial.gov)Phase II
10-434Randomized Study of Early Palliative Care Integrated with Standard Oncology Care versus Standard Oncology Care Alone in Patients with Advanced Lung and Non-colorectal Gastrointestinal Malignancies  (View details on clinicaltrial.gov)N/A
11-436Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer  (View details on clinicaltrial.gov)Phase II
12-401Randomized, Double-Blind, Placebo Controlled Phase II Study of FOLFOX +/- Ziv-Aflibercept in Patients With Advanced Esophageal and Gastric Cancer  (View details on clinicaltrial.gov)Phase II
14-247Randomized, multicenter, PHASE III, Open-label Study of Alecetinib versus Crizotinib in treatment-naive alk-positive advanced non-small cell lung cancer  (View details on clinicaltrial.gov)Phase III
13-196Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With or Without Trastuzumab in Patients With 'Traditional' and 'Non-Traditional' HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy  (View details on clinicaltrial.gov)Phase II
09-042RRP450 - Phase I Trial in Liver Metastases and Primary Liver Tumors  (View details on clinicaltrial.gov)Phase I
08-046RTOG 0534: A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy  (View details on clinicaltrial.gov)Phase III
10-095RTOG 0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer  (View details on clinicaltrial.gov)Phase III
12-055RTOG 0848: A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma  (View details on clinicaltrial.gov)Phase III
10-040RTOG 0926: A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Cisplatin Chemotherapy Following a Thorough Transurethral Surgical Restaging  (View details on clinicaltrial.gov)Phase II
11-163RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma  (View details on clinicaltrial.gov)Phase III
13-295RTOG 1112: Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma  (View details on clinicaltrial.gov)Phase III
12-515RTOG 1115: Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) With a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT With a GNRH Agonist and TAK-700 For Men With High Risk Prostate Cancer  (View details on clinicaltrial.gov)Phase III
13-338RTOG 1205: Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma  (View details on clinicaltrial.gov)Phase II
13-059SARC016: Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors  (View details on clinicaltrial.gov)Phase II
278 clinical trials listed.

Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.